HIF‐1α and PD‐L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer
World Journal of Surgery · 2026-05 · 50 (5) · 1169-1178
DOI: 10.1002/wjs.70352 ↗At a glance
Journal article in World Journal of Surgery, published online on 2026-04-02. Written by Lin Lu and 3 co-authors. Institution: Department of Oncology, Shangdong Provincial Key Medical and Health Discipline, Qingdao Central Hospital, University of Health and Rehabilitation Sci…. Major MEDLINE topics: Rectal Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, B7-H1 Antigen, Neoadjuvant Therapy. Cited 1 times so far (Crossref); 45 references.
Abstract (original language)
Background
NCRT is a standard preoperative treatment for locally advanced RC with variable efficacy. This prospective cohort study explored HIF‐1α and PD‐L1 expression in RC and their impact on NCRT efficacy to provide a theoretical basis for effective predictive indicators.
Methods
Patients with locally advanced rectal cancer ( n = 128) (cT3/T4‐N0 or cTany‐N1/N2) were prospectively enrolled. General clinical data were collected. Preoperative tumor and adjacent non‐tumor tissues were obtained via pre‐treatment biopsy, and HIF‐1α/PD‐L1 expression was detected by qRT‐PCR. All patients underwent radical surgery after NCRT, with efficacy evaluated by pTRG. ROC analysis assessed the predictive value of HIF‐1α/PD‐L1 for NCRT response. Logistic regression analyzed HIF‐1α/PD‐L1 independent association with NCRT efficacy. The 5‐year follow‐up recorded survival/recurrence; Kaplan‐Meier analyzed DFS/OS, and COX regression explored the independent correlation between HIF‐1α/PD‐L1 mRNA levels and post‐NCRT DFS/OS.
Results
HIF‐1α and PD‐L1 were highly expressed in tumor tissues, with higher levels in NCRT‐insensitive patients. Combined HIF‐1α and PD‐L1 showed better AUC for predicting NCRT insensitivity than either alone (AUC = 0.706, sensitivity = 63.24%, specificity = 73.33%). For each 1‐unit increase in HIF‐1α and PD‐L1, the risk of recurrence in patients increased by 1.567‐fold ( p = 0.001, HR = 1.567, 95% CI = 1.216–2.018), and the risk of death increased by 1.725‐fold ( p = 0.000, HR = 1.725, 95% CI = 1.354–2.200).
Conclusion
HIF‐1α and PD‐L1 expression can serve as reliable indicators for predicting NCRT efficacy and poor prognosis in RC patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Oncology, Shangdong Provincial Key Medical and Health Discipline, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China.
ORCID profiles: Qingye Zhao
Cite
APA
Lu, L., Zhang, L., Chai, J., & Zhao, Q. (2026). HIF‐1α and PD‐L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer. World Journal of Surgery, 50(5), 1169-1178. https://doi.org/10.1002/wjs.70352
Vancouver
Lu L, Zhang L, Chai J, Zhao Q. HIF‐1α and PD‐L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer. World Journal of Surgery. 2026;50(5):1169-1178. doi:10.1002/wjs.70352
BibTeX
@article{Lu2026,
author = {Lu, Lin and Zhang, Linlin and Chai, Jie and Zhao, Qingye},
title = {HIF‐1α and PD‐L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer},
journal = {World Journal of Surgery},
year = {2026},
volume = {50},
number = {5},
pages = {1169--1178},
doi = {10.1002/wjs.70352}
}
EUVIMED